Ascentage Pharma Announces Board and Committee Changes
Ticker: AAPG · Form: 6-K · Filed: Dec 31, 2025 · CIK: 2023311
Sentiment: neutral
Topics: governance, board-changes, committee-establishment
TL;DR
Ascentage Pharma reshuffled board committees and appointed a new Lead Independent Director on Dec 30, 2025.
AI Summary
On December 30, 2025, Ascentage Pharma Group International announced changes to its board and committees. These include a change in the composition of the Nomination Committee, the appointment of a Lead Independent Non-Executive Director, and the establishment of a Research and Development Committee. The company also provided a supplemental announcement.
Why It Matters
These changes indicate a restructuring of the company's governance and oversight, particularly in areas related to nominations and research and development, which could impact strategic direction.
Risk Assessment
Risk Level: low — The filing details routine corporate governance changes and does not present immediate financial or operational risks.
Key Players & Entities
- Ascentage Pharma Group International (company) — Filer of the report
FAQ
What specific changes were made to the Nomination Committee?
The filing states there was a 'Change In Composition of Nomination Committee' but does not detail the specific changes in this excerpt.
Who was appointed as the Lead Independent Non-Executive Director?
The filing mentions the 'Appointment of Lead Independent Non-Executive Director' but does not name the individual in this excerpt.
What is the purpose of the newly established Research and Development Committee?
The filing announces the 'Establishment of Research and Development Committee' but does not specify its purpose in this excerpt.
When were these announcements made?
The announcements were made on December 30, 2025.
Does Ascentage Pharma file annual reports under Form 20-F or 40-F?
Ascentage Pharma indicates it files annual reports under Form 20-F.
Filing Stats: 253 words · 1 min read · ~1 pages · Grade level 13.3 · Accepted 2025-12-31 08:00:08
Filing Documents
- ea0271399-6k_ascent.htm (6-K) — 11KB
- ea027139901ex99-1_ascent.htm (EX-99.1) — 15KB
- ea027139901ex99-2_ascent.htm (EX-99.2) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- ex99-2_001.jpg (GRAPHIC) — 5KB
- 0001213900-25-126812.txt ( ) — 53KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of December 2025 Commission File Number: 001-42484 ASCENTAGE PHARMA GROUP INTERNATIONAL (Translation of Registrant’s name into English) 68 Xinqing Road Suzhou Industrial Park Suzhou, Jiangsu China (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE On December 30, 2025, Ascentage Pharma Group International issued two announcements. The first is entitled “(1) Change In Composition of Nomination Committee; (2) Appointment of Lead Independent Non-Executive Director; (3) Establishment of Research and Development Committee; and (4) Supplemental Announcement on Further Grant of Awards Under The 2022 RSU Scheme and Grant of Options Under The Post IPO Share Option Scheme”. The second is entitled “List of directors and their roles and functions”. A copy of the announcements is furnished as Exhibits 99.1 and 99.2 to this Report. 1 INDEX TO EXHIBITS Exhibit Number Exhibit Title 99.1 Announcement dated December 30, 2025 99.2 Announcement dated December 30, 2025 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ASCENTAGE PHARMA GROUP INTERNATIONAL Date: December 31, 2025 /s/ Dajun Yang Name: Dajun Yang Title: Chief Executive Officer 3